MMC USA Blue Shark capsules

Safety advisory

28 April 2015

MMC USA Blue Shark capsules pose a serious risk to your health and should not be taken.

The Therapeutic Goods Administration (TGA) has tested a product labelled MMC USA Blue Shark capsules and found that:

  • image one of the MMC USA blue shark capsules packagingthe capsules contain the undeclared substance sildenafil
  • consumers are advised that sildenafil is a prescription-only substance.

The supply of MMC USA Blue Shark capsules is illegal.

MMC USA Blue Shark capsules have not been assessed by the TGA for quality, safety or efficacy as required under Australian legislation, and the place of manufacture is not approved by the TGA.

image of the MMC USA blue shark capsules packaging and capsulesTGA investigations have shown that a number of people in Australia may have bought the product online.

Information for consumers

  • Stop taking MMC USA Blue Shark capsules and take any remaining capsules to your local pharmacy for safe disposal.
  • If you have any concerns arising from your use of this product, consult your health care practitioner.

Action the TGA is taking

image of the MMC USA blue shark capsules blister packThe TGA is working with Australian Customs and Border Protection Service (ACBPS) to help stop future shipments of MMC USA Blue Shark capsules from entering Australia.

If these capsules are found at the border by ACBPS they will be seized and destroyed.

The TGA is advising consumers to exercise extreme caution when purchasing medicines from unknown overseas Internet sites. Products purchased over the Internet:

  • may contain undisclosed and potentially harmful ingredients
  • may not meet the same standards of quality, safety and efficacy as those approved by the TGA for supply in Australia.

Report counterfeit medicines and medical devices

If you are worried about counterfeit medicines or medical devices, and want to report an issue, you can report the matter to the TGA:

Phone: 1800 020 653
Online: Report a perceived breach of the Therapeutic Goods Act or questionable practices relating to therapeutic products
Email: info@tga.gov.au